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Immunoglobulin (Ig) replacement therapy is effective in reducing infections in patients with
primary antibody deficiency (PAD). Diversity of specific antibodies is achieved by pooling
plasma from over 1000 donors usually of a given geographic region. However, there is no
agreement with regard to an optimal vaccination schedule for plasma donors. Especially
for tick-borne encephalitis (TBE), regional vaccination rates differ widely among populations
due to the epidemiology of the disease. We analyzed specific antibody titers against TBE
in comparison to total IgG levels in 162 serum samples collected from 110 PAD patients
substituted with polyvalent intravenous IgG or subcutaneous IgG. Some patients received
different IgG products over time leading to a total number of 122 different patient-IgG
product combinations. Positive TBE-specific IgG levels were detected in 35 cases when
measured by standard ELISA and could be confirmed by demonstration of neutralizing anti-
bodies in 31 cases.The detection of specific antibody levels correlated with the geographic
origin of the IgG preparations. No titers were detectable in patients substituted with IgG
products from North-American donors, whereas variable degrees of anti-TBE titers were
observed in patients receiving products from different European countries. We suggest
considering the patients’ personal risk for TBE when selecting an appropriate Ig prepara-
tion. These data support regional plasma donation in order to address the diverse local
infection profile.
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INTRODUCTION
Distribution of tick-borne encephalitis (TBE) is known to show
immense geographic differences leading to variable need for
vaccination-induced protection of individuals (1). Patients suf-
fering from primary antibody deficiency (PAD) are characterized
by reduced or absent antibody responses following vaccination1.
They depend on continuous Immunoglobulin G (IgG) replace-
ment therapy to maintain a diverse antibody repertoire. Plasma-
producing companies recruit plasma donors globally and the
origin of plasma donors varies considerably in between com-
mercially available IgG products even between different batches
of the same product. The proof of representative specific anti-
body titers within the products is obligatory for authorization of
each batch. Quality management within the companies often pro-
vides data for an even broader spectrum of specific antibodies, but
usually not anti-TBE IgG titers. Rabel et al. reported 2012 geo-
graphic variation of neutralizing antibodies against TBE within
intravenous IgG preparations (2). Seidel et al. mention passive
transfer of protective anti-TBE IgG levels via IgG replacement
1http://www.esid.org
therapy in their publication focusing on active TBE vaccination
responses in 18 patients (3). However, protective antibody levels
within patients have not been systematically studied so far. Epi-
demiological data on the prevalence of TBE infection within PAD
patients do not exist, so it can only be speculated that PAD patients
require analogous TBE prevention to the healthy population of
their region.
Therefore, the prevalence of protective anti-TBE IgG levels in
PAD patients under IgG replacement therapy was assessed in this
study in order to develop a strategy for patient care in individuals
at high risk to TBE exposure.
MATERIAL AND METHODS
STUDY COHORT
Analysis was performed in serum samples collected between 2003
and 2008 and supplemented by samples from 2014 from recently
approved IgG products. One hundred ten patients with diagnosed
PAD according to the ESID definitions1 were included after sign-
ing informed consent according to ethical approval (vote number
239/07, Ethics Committee University Medical Center Freiburg).
All patients received regular intravenous or subcutaneous IgG
replacement therapy without recent change of brand. Additional
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information about patient history (such as history of tick bite,
meningitis in general, and previously performed TBE vaccina-
tion) and on B-cell phenotype according to Freiburg classification
(4) and Euro-Class (5) was recorded. In patients receiving IVIG
therapy blood samples obtained immediately prior to infusion
provided trough level values, others were indicated as non-trough
level measurements. Serum samples were analyzed both retro- and
prospectively. In 8 patients, TBE titers were determined under two
and in 2 patients under three different Ig preparations leading to a
total of 122 cases of patient-preparation combinations. In 29 of the
122 cases, two or more consecutive measurements were performed
over time to test for reproducibility.
LABORATORY ASSESSMENTS
Total serum IgG was measured by nephelometry using standard
test kits (Dade-Behring kit, BN II nephelometer).
The SERION ELISA classic TBE Virus IgG test is a qualitative
and quantitative immunoassay for the detection of human anti-
bodies in serum, plasma, or cerebrospinal fluid directed against
TBE viruses. The antibody activity is expressed in units per milli-
liter with a cut-off at 150 U/ml and a grey zone between 100 and
150 U/ml. The evaluation of the IgG antibody activity is referenced
to the first standard serum for human IgG antibodies against TBE
Virus of the Consultant Laboratory for TBE Viruses located at
the Robert Koch Institute (RKI) in Berlin, Germany. Samples col-
lected before 2013 were measured with an earlier version of the
immunoassay with a different unitation. According to the manu-
facturer, a factor of 5.6 may be used for conversion of old values
in new standard values. All results are therefore expressed in units
per milliliter according to the new RKI standard. For details of the
methods, we refer to the manufacturer’s information.
The recombinant ED3 immune complex ELISA was performed
as described before (6). Briefly, microtiter plates were coated with
rheumatoid factor IgM (10 g/ml PBS+ 1 mg/ml NaN3). The plates
were blocked (1 h; 10 mg/ml bovine serum albumin in PBS) and
washed (Tris-Tween) and stored at−80°C before use. Human sera
were diluted 1:10 in PBS+ 2% BSA. In each assay, two standard
positive and three negative control samples were included. To 25µl
of diluted serum, 25µl of peroxidase-labeled ED3 antigen, diluted
1:20,000, were added. The plates were incubated at 4°C over night.
After washing 50µl TMB (tetramethylbenzidine) substrate was
added to each well and the reaction was stopped after 10 min by
adding 50µl of H2SO4 stopping solution. The reaction is read at
450 nm. The cut-off of the assay is at 0.150 OD with a gray zone
between 0.100 and 0.150 OD. Results are calculated by dividing the
OD of the sample by 0.150 and expressed as Signal/Cut-off (S/Co).
IgG PRODUCTS
Data on the origin of plasma donors were taken from the respective
product information or were provided by courtesy of the com-
panies. Epidemiological data concerning vaccination frequencies
among different European populations have been reported for
2007–2009 by Kunze et al. and are listed in Table 1 (7).
Up to date there exists no licensed TBE vaccine in the USA2.
2http://wwwnc.cdc.gov/travel/
Table 1 | Vaccination rates of different European countries 2007–2009.
Country Vaccination rate (%)
Austria 58 (88% incomplete)
Latvia 39
Germany 26
Estonia 20
Switzerland 17
Czech Republic 16
Sweden 13
Slovenia 13
Lithuania 10
Table 2 | Origin of plasma – assignment of product codes.
Product codes North American Mixture European
IVIG 1, 2, 3, 4 5, 6, 7 8, 9
SCIG 10 11, 12 13
Due to these aspects, plasma preparations were grouped as
North American, European, or a mixture of both in this analysis
(Table 2).
RESULTS
Anti-TBE-specific IgG values were measured by a standard ELISA
(Serion) in relation to total IgG levels for IVIG (Figure 1A)
and for SCIG preparations (Figure 1B). Overall, 75 negative, 12
intermediate, and 35 positive results were detected with 33 nega-
tive, 7 intermediate, and 20 positive cases for IVIG preparations
(Figure 1A) and 42 negative, 5 intermediate, and 15 positive cases
for SCIG preparations (Figure 1B).
Products with North-American origin never achieve anti-TBE-
specific IgG levels above 150 U/ml in patients (25 negative and 2
intermediate cases). For both mixed and European products in 35
out of 95 cases, positive anti-TBE titers can be detected (compared
to 50 negative and 10 intermediate results). There were clear differ-
ences between single products in this group revealing the highest
titers of anti-TBE antibodies in the IVIG products 5, 7, and 9 and
the SCIG product 11, while there were no truly positive serum
titers achieved in patients on products 8, 12, and 13. Product 6 was
applied only in one case with insufficient IgG serum trough levels
at the point of measurement and can therefore not be judged.
Based on our previous data (4, 8), in two cases with positive
anti-TBE titers, a sustained active anti-TBE vaccination response
could not be excluded because of the combination of normal
switched memory B-cell counts and a history of vaccination
against TBE virus.
The distribution of cases was analyzed according to the anti-
TBE response for each of the 13 products (Figure 2). Cases
were restricted to cases with IgG trough levels above 7 g/l. This
confirmed the previously identified four products with mostly
positive anti-TBE serum levels (5, 7, 9, and 11) and eight prod-
ucts with mostly negative/intermediate anti-TBE serum levels (1,
2, 3, 4, 8, 10, 12, and 13). Again, all North-American products, but
also some purely European products (8 and 13) were negative,
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FIGURE 1 | Anti-TBE IgG vs. total IgG serum levels in patients under
IgG replacement therapy. Anti-TBE IgG titers measured by standard
ELISA are shown in relation to total IgG serum levels for 60 cases from
patients treated with IVIG (A) and 62 cases from patients treated with SCIG
products (B). Each case of patient-product combination is presented by a
single value. Product codes are assigned to symbols with dotted filling
representing North-American origin of plasma, gray filling mixed origin, and
black filling European origin. The anti-TBE antibody titers for positive
(>150 U/ml), intermediate (100–150 U/ml), and negative (<100 U/ml) serum
titers are marked. In four cases on IVIG replacement with positive anti-TBE
titers, only non-trough levels were available (NT). Positive values are also
marked in two cases where a sustained active anti-TBE antibody response
cannot be excluded because of normal switched memory B cells and
vaccination (*).
reflecting the regional heterogeneity of the vaccination status
against TBE in Europe. Unfortunately, more detailed information
on the composition of mixed and European products regarding
the specific country of origin and the particular mixture of single
plasma batches is not routinely available through the producing
companies.
To assess the reproducibility of the results, consecutive trough
serum samples within 29 cases were analyzed for global anti-TBE
titers (Figure 3). Twenty-two cases showed stable measurements at
different time points with consistently negative or positive results.
At overall grading in negative, intermediate, and positive results,
five cases (7, 8, 10, 25, and 26) had values in the intermediate region
and in two cases (12 and 14) the titers clearly varied (indicated by
#), which is not explained by parallel variations in total IgG serum
levels (data not shown).
Standard anti-TBE IgG ELISAs are known to have limited infor-
mative value in regard to actual protection. More informative
FIGURE 2 | Stratification of cases for each product in patients with IgG
trough levels above 7 g/l. All cases with total IgG trough levels above 7 g/l
were stratified into positive, intermediate, and negative results in the
standard anti-TBE ELISA according to IgG products as coded inTable 2.
Plasma origin is indicated as North America (“NA”), mixture (“M”), and
Europe (“E”).
assays detecting neutralizing antibodies on the other hand are
currently rarely performed and more elaborate. We confirmed the
findings of the standard ELISA in a selection of 46 cases in a test
for neutralizing antibodies with an ELISA for anti-ED3 of TBE
antibodies (Figure 4; Table 3). Our data show that 31 out of the
35 positive results from the standard ELISA could be confirmed by
the detection of neutralizing antibodies. Standard ELISA results in
the lower positive range (150–200 U/ml) changed to intermediate
or even negative in three cases or were confirmed as positive in
another three cases. Standard ELISA results above 200 U/ml were
confirmed positive for neutralizing antibodies in all cases. Sin-
gle random samples from intermediate or negative results in the
standard ELISA always turned out to be negative for neutralizing
antibodies as expected (Table 3).
DISCUSSION
Due to disease-associated impairment of vaccination responses,
patients with primary antibody deficiencies depend on the quality
and quantity of passive protection via the application of polyva-
lent IgG preparations. For most diseases including TBE, which can
be prevented by vaccination, the induced protection is provided
via antibodies. The impact of geographic plasma origin on the
presence of distinct specific IgG titers within polyvalent IgG prepa-
rations has been described before. Rabel et al. had already reported
geographic differences for TBE within IVIG products (2). In par-
allel, Seidel et al. found divergent levels of protective antibodies
in a small number of patients with IgG replacement therapy but
did not correlate their findings to the geographic plasma origin in
detail (3). Our data complement the previous results by analyzing
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FIGURE 3 | Cases with consecutive measurements. The dot plot displays anti-TBE IgG titers from the standard ELISA for 29 separate cases with consecutive
measurements. Cases with inconsistent ratings are highlighted by “#.” The variation of specific anti-TBE IgG titers was not due to variation in total IgG serum
levels.
FIGURE 4 | Comparison of global vs. neutralizing anti-TBE IgG titers.
Quantitative test results for global standard anti-TBE IgG titers from the
standard ELISA are compared to neutralizing, anti-recombinant ED3
immune complex ELISA values within identical serum samples. Circles filled
in black indicate positive and open circles indicate negative results in both
tests. Gray and dotted fillings reflect deviant grading within the two assays.
TBE-specific serum titers in patients in relation to the geographic
origin of the received IgG preparation.
An epidemiological proof of protection against TBE infection
is impossible given the small number of CVID patients under sub-
stitution, but we could show a good correlation of high anti-TBE
IgG titers in the global ELISA (>200 U/ml) and the presence of
anti-ED3 neutralizing antibodies. Antibodies directed to the ED3
protein of TBE virus are highly specific for TBE virus without cross
reactivity to other flaviviruses and have shown strong neutralizing
activity and are thought to be protective against TBE (6, 9–11). In
contrast, reactivity in global anti-TBE ELISAs using lysate of cell
Table 3 | Comparison of standard ELISA for anti-TBE IgG vs.
neutralizing antibodies.
Serion ELISA
result
Neutr. Ab
neg
Neutr. AB
intermed.
Neutr. AB
positive
Neutr. AB
not tested
75 negative 10 0 0 65
12 intermediate 2 0 0 10
35 positive 1 2 31 1
cultured virus, may not always be due to neutralizing antibodies
and cross reactivity with other flaviviruses, e.g., yellow fever virus
or dengue virus cannot be excluded (12). Our data demonstrate
strong differences in TBE-specific IgG titers among patients under
IgG substitution depending on the origin of plasma. In 35 patients,
anti-TBE titers were positive with positive evidence of protective
neutralizing antibodies in most cases.
All purely North-American products were consistently nega-
tive being in line with the previously published findings from
measurements within IVIG products (2). The results for mixed
and European products were variable with 26 positive, 5 inter-
mediate, and 30 negative results looking at cases with total IgG
trough levels above 7 g/l. This variability among IgG preparations
with European plasma contribution was highly dependent on the
specific product. Most patients under replacement with products
5, 7, 9, and 11 had positive results, while serum samples from
patients with products 8, 12, and 13 were negative or intermedi-
ate. It is tempting to speculate that the content of North-American
plasma is of major influence in the mixed group. However, given
the variability within purely European-derived plasma products,
it becomes clear that the country of origin within Europe has a
similarly strong influence as disclosed already by the different vac-
cination policies in Table 1. Even within a given product variable,
anti-TBE serum titers were found as exemplified by product 9 sug-
gesting that over time the composition of different batches varied
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in regard to origin, mixture, and obviously specific donors within
the countries. Due to lack of detailed information on the relative
composition of the batches applied currently treating physicians
have no chance to predict the presence of protective levels for spe-
cific products. This would not only require the disclosure of the
composition of the specific batches by the plasma-producing com-
panies but also a better estimate of an average value of national
anti-TBE titers in European countries, which may vary according
to changing policy over time and therefore is not feasible.
In daily practice, we suggest physicians to consider the patient’s
personal risk for specific infection, in this case TBE, as one aspect
when selecting an appropriate IgG preparation at the initiation of
IgG replacement therapy.
For patients already on IgG replacement therapy, we recom-
mend the following approach for patients at high risk for TBE
exposure:
A) Patients receiving IgG products with definitive exclusive
plasma origin from North America: no anti-TBE IgG testing
is necessary. The patient needs to be informed, that no passive
protection can be expected. Other types of prophylaxis need to
be emphasized. Whether a change of product with the option
of a passive protection is justified has to be made by individual
decision.
B) All others patients: standard anti-TBE ELISA testing at the time
of trough levels is suitable. In serum samples with anti-TBE
titers above 200 U/ml, the presence of protective neutraliz-
ing antibodies can be assumed. However, patients need to be
informed about possible variations due to changes in batch
composition. In case of negative or intermediate result in high-
risk patients, such as lumberjacks in endemic areas, it might
be helpful to contact the producing company for disclosure of
the definite composition of the relevant batch. This should be
added by the information whether in this individual case the
patient could be provided with selective batches containing
higher amounts of plasma from distinct European countries
with better TBE vaccination rates.
However, this procedure still bears uncertainties due to vari-
ation between single batches of the same product. Therefore,
we recommend plasma-producing companies within the Euro-
pean market to add measurements of anti-TBE IgG within each
charge and to provide physicians treating PAD patients with these
data. Alternatively, the display of a defined code within the batch
numbers for the countries of plasma origin might enable treating
physicians to choose products based on the national vaccination
policies described above.
These data emphasize the importance of regional plasma dona-
tion to address the diverse local infection profiles in a better way.
Patients with PAD lacking specific antibody responses depend on
the broad passive protection of the IgG preparations provided by
plasma-producing manufacturers. Optimal vaccination status of
the plasma donors according to official regional recommendations
can greatly contribute to the quality of the product.
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